Ribo Life-B (06938) Jumps Over 5% Intraday After EU Phase I Clinical Trial Application for RBD3133 Injection

Stock News14:16

Ribo Life-B (06938) rose more than 5% during intraday trading. As of press time, the stock was up 3.64% at HK$55.55, with a turnover of HK$14.7097 million.

On the news front, Ribo Life announced that it has submitted a Phase I clinical trial application in the European Union for RBD3133 injection, an siRNA product targeting INHBE, with overweight and obesity as the therapeutic indication.

The trial will provide the first-in-human evaluation of RBD3133 and will lay the foundation for further clinical development.

RBD3133 represents a key milestone in the company's siRNA product development portfolio in the cardiovascular and metabolic disease area, and is expected to become a cornerstone drug for the treatment of weight-loss-related cardiovascular and metabolic diseases.

As the company's first drug candidate in the obesity treatment field, RBD3133 reflects the company's strategic focus on developing innovative drugs for a large patient population with significant unmet medical needs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment